It’s The Overall Survival, Sponsors! Ovarian Cancer Indications Withdrawn For Three PARP Inhibitors
Executive Summary
PARP inhibitors appear to be getting the same kind of scrutiny that US FDA has given to P13K inhibitors. AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis’ Rubraca have indications voluntarily withdrawn after ‘potential detrimental effect’ on overall survival seen in randomized clinical trials.
You may also be interested in...
GSK Stays Ahead Of AstraZeneca With New Survival Data In Endometrial Cancer
The companies are competing to prove the value of their PD1/L1 therapies in all endometrial cancer patients - but questions remain about the benefits of adding PARP inhibitors with the latest data from the RUBY and DUO-E Phase III studies.
Stock Watch: Queasiness After The Humira Banquet
The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.
Keeping Track: Accelerated Approval Wins (Padcev+Keytruda) And Losses (Imbruvica To Shed MCL, MZL Claims)
The latest drug development news and highlights from the Pink Sheet's US FDA Perfomance Tracker.